ASCENTAGE-B (06855) announced its interim results for the six months ended June 30, 2025, reporting revenue of RMB 234 million. Sales of Nerlynx® (olverembatinib) in China increased by RMB 105 million or 93% to RMB 217 million in the first half of 2025, compared to RMB 113 million for the six months ended June 30, 2024.

Research and development expenses for the six months ended June 30, 2025 increased by RMB 84.5 million or 19.0% to RMB 529 million, primarily due to higher external R&D costs related to the Group's ongoing global clinical trials.

The Group's core products, olverembatinib and lisaftoclax, are being developed to treat various major hematological malignancies and solid tumors globally. For hematological malignancies, Nerlynx® (olverembatinib) is targeted for or intended to treat chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), while Lisanabotoclax® (lisaftoclax) is targeted for or intended to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and multiple myeloma (MM).

According to an independent industry report commissioned by the Group and prepared by Frost & Sullivan, the combined market size for these specific hematological diseases alone is expected to exceed $160 billion by 2035.

Leveraging strong internal R&D capabilities, the Group has established a global intellectual property portfolio. As of June 30, 2025, the Group held a total of 478 granted patents worldwide, including over 20 new patents granted during the reporting period (excluding certain expired and abandoned patents unrelated to the Group's core product portfolio). As of the end of the reporting period, 342 granted patents were authorized overseas.

The Group has also established collaborations and other relationships with leading global biotechnology and pharmaceutical companies, including collaboration and licensing agreements with Innovent Biologics, as well as clinical collaboration agreements with AstraZeneca, Merck, and Pfizer. The Group has also formed R&D partnerships with leading research institutions, including but not limited to Dana-Farber Cancer Institute, Mayo Clinic, MD Anderson Cancer Center, National Cancer Institute, and University of Michigan.